Dr Rajat Bannerji speaks to ecancer at the ASH 2019 meeting in Orlando about dose escalation of REGN1979, an anti-CD30 x anti-CD3 antibody, in patients with relapsed or refractory B-cell non-Hodgkins lymphoma.
He reports that there have been no dose-limiting toxicities up to the final dose level, although most of the toxicities that did occur were experienced at lower doses during the first weeks of treatment.
Dr Bannerji says that the study is continuing in the expansion cohorts, and explains the steps necessary to take this drug to approval as well as discussing potential combination therapies.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.